S&P 500
$5,958.38
+0.7%
+$41.45
DJI
$42,654.74
+0.8%
+$331.99
NASDAQ
$19,211.10
+0.5%
+$98.78
Bitcoin
$103,192.00
-0.8%
-$786.22
AAPL
$211.31
-0.1%
-$0.14
AMZN
$205.54
+0.2%
+$0.37
GOOG
$167.32
+1.2%
+$1.92
META
$640.11
-0.6%
-$3.77
MSFT
$453.88
+0.2%
+$0.75
NVDA
$135.20
+0.3%
+$0.38
TSLA
$349.44
+1.9%
+$6.62
SpringWorks Therapeutics (NASDAQ: SWTX)
$46.12
(0.1%)
$0.04
Price as of May 16, 2025, 3:58 p.m. ET
SpringWorks Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
SpringWorks Therapeutics Company Info
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
News & Analysis
Featured Article
What Company Will Eli Lilly Buy Next?
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
David Haen | Jan 23, 2020
Featured Article
Here's Why SpringWorks Therapeutics Climbed 69% in December
The stock climbed after investors saw encouraging signs from a similar program.
Cory Renauer | Jan 12, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.